Optum Pharmacy 702, LLC
Optum Pharmacy 702, LLC was paid $55.06M by Medicaid between Jan 2018 and Dec 2024, across 21 billing codes. Its largest line is J0585, Injection, onabotulinumtoxina, 1 unit — 37% of everything it billed.
JEFFERSONVILLE, IN 47130
Next to other Durable Medical Equipment & Medical Supplies providers in Indiana
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,591 | $4.00M | |
| 2019 | 4,288 | $6.47M | |
| 2020 | 5,546 | $7.48M | |
| 2021 | 6,852 | $9.99M | |
| 2022 | 6,521 | $9.67M | |
| 2023 | 6,179 | $9.70M | |
| 2024incomplete | 5,378 | $7.75M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | 37% | 16,400 | 14,513 | $20.47M |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | 11% | 4,161 | 3,296 | $5.90M |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | 9.7% | 2,321 | 1,584 | $5.32M |
| J2357 | Injection, omalizumab, 5 mg | 9.0% | 2,328 | 1,990 | $4.95M |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | 8.9% | 3,364 | 2,628 | $4.93M |
| J2315 | Injection, naltrexone, depot form, 1 mg | 8.0% | 3,410 | 3,055 | $4.42M |
| J2323 | Injection, natalizumab, 1 mg | 3.7% | 361 | 260 | $2.02M |
| J2182 | Injection, mepolizumab, 1 mg | 3.6% | 831 | 592 | $1.99M |
| J0517 | Injection, benralizumab, 1 mg | 3.1% | 386 | 340 | $1.68M |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | 1.9% | 912 | 695 | $1.04M |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 1.4% | 658 | 550 | $785K |
| J0897 | Injection, denosumab, 1 mg | 1.4% | 582 | 510 | $745K |
9 more codes
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 141 | $411K |
| J2356 | Injection, tezepelumab-ekko, 1 mg | <1% | 78 | $232K |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | <1% | 80 | $105K |
| J3490 | Unclassified drugs | <1% | 61 | $59K |
| 90378 | <1% | 101 | $8K | |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 254 | $905.14 |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | <1% | 453 | $624.24 |
| S5000 | Prescription drug, generic | <1% | 61 | $337.94 |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | <1% | 412 | $173.34 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.